Signalisation JAK/STAT
Les inhibiteurs de la signalisation JAK/STAT sont des composés qui perturbent la voie des kinases Janus (JAK) et du transducteur et activateur de transcription (STAT), impliquée dans la signalisation des cytokines, la croissance cellulaire et la réponse immunitaire. Ces inhibiteurs sont des outils importants pour étudier la régulation de cette voie et son rôle dans diverses maladies, notamment les cancers, les troubles immunitaires et les affections inflammatoires. Les inhibiteurs JAK/STAT sont également en cours de développement en tant que thérapies ciblées pour ces maladies. Chez CymitQuimica, nous offrons une large sélection d'inhibiteurs de haute qualité de la signalisation JAK/STAT pour soutenir vos recherches en biologie moléculaire, oncologie et immunologie.
Sous-catégories appartenant à la catégorie "Signalisation JAK/STAT"
321 produits trouvés pour "Signalisation JAK/STAT"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
BP-5-087
CAS :<p>BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia.</p>Formule :C36H30F8N2O6SCouleur et forme :SolidMasse moléculaire :770.69Galiellalactone
CAS :<p>inhibits IL-6-mediated JAK/STAT signal transduction</p>Formule :C11H14O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :194.23CP-690550A
CAS :<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Formule :C15H21N5O2Couleur et forme :SolidMasse moléculaire :303.36GDC-4379
CAS :<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Formule :C21H18ClF2N7O3Couleur et forme :SolidMasse moléculaire :489.86Peficitinib hydrobromide
CAS :<p>Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.</p>Formule :C18H23BrN4O2Couleur et forme :SolidMasse moléculaire :407.312Povorcitinib
CAS :<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>Formule :C23H22F5N7OCouleur et forme :SolidMasse moléculaire :507.469(2R,5S)-Ritlecitinib
CAS :<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Formule :C15H19N5OCouleur et forme :SolidMasse moléculaire :285.34YM-341619
CAS :<p>YM-341619 (AS1617612), potent STAT6 inhibitor; IC50: 0.70 nM; hinders IL-4-induced Th2 in mice; may aid allergic disease research.</p>Formule :C22H21F3N6O2Couleur et forme :SolidMasse moléculaire :458.44TUL01101
CAS :<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>Formule :C22H25F2N5O2Couleur et forme :SolidMasse moléculaire :429.46Stafia-1-dipivaloyloxymethyl ester
CAS :<p>Stafia-1 suppresses pSTAT5a in a dose-dependent manner (0-200 μM) without affecting pSTAT5b.</p>Formule :C37H48FO13PCouleur et forme :SolidMasse moléculaire :750.74MM-206
CAS :<p>MM-206, a cell-permeable, non-cytotoxic naphthalene sulfonamide compound, it effectively inhibits STAT3 DNA-binding activity.</p>Formule :C22H12F5NO3S2Couleur et forme :SolidMasse moléculaire :497.46MC0704
<p>MC0704: STAT3 inhibitor, IC50=2.13μM, promotes apoptosis & cell arrest, anti-breast cancer, for mTNBC research.</p>Formule :C29H21BrN4O2Couleur et forme :SolidMasse moléculaire :537.41STAT3-IN-15
<p>STAT3-IN-15: Potent, oral STAT3 inhibitor for IPF, blocks STAT3 phosphorylation, cell migration, and EMT.</p>Formule :C20H17F3N2O3SCouleur et forme :SolidMasse moléculaire :422.42Thi-DPPY
CAS :<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>Formule :C28H28ClN5O4SCouleur et forme :SolidMasse moléculaire :566.07HJC0149
CAS :<p>HJC0149 is a potent orally bioavailable signal transducer and activator of transcription 3 inhibitor.</p>Formule :C15H10ClNO4SCouleur et forme :SolidMasse moléculaire :335.76TYK2-IN-11
CAS :<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Formule :C18H17N5O3SCouleur et forme :SolidMasse moléculaire :383.42SYK/JAK-IN-1
CAS :<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>Formule :C24H26N8O3Couleur et forme :SolidMasse moléculaire :474.52PF-00956980
CAS :<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Formule :C18H26N6OCouleur et forme :SolidMasse moléculaire :342.44LLL12
CAS :<p>LLL12 inhibits STAT3 phosphorylation, boosting Cisplatin and Paclitaxel effects against ovarian cancer cell activities.</p>Formule :C14H9NO5SCouleur et forme :SolidMasse moléculaire :303.29JAK-IN-10
CAS :<p>JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.</p>Formule :C20H18FN5O3SDegré de pureté :99.53%Couleur et forme :SolidMasse moléculaire :427.45JAK3-IN-1
CAS :<p>JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.</p>Formule :C26H30ClN7O2Couleur et forme :SolidMasse moléculaire :508.02JAK3/BTK-IN-1
CAS :<p>JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important</p>Formule :C25H28N8ODegré de pureté :97.89%Couleur et forme :SolidMasse moléculaire :456.54JAK-IN-30
CAS :<p>JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50</p>Formule :C19H26N8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :398.53JAK-IN-28
CAS :<p>JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].</p>Formule :C20H18ClN7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :407.86AZD-1897
CAS :<p>AZD-1897 is a highly efficient ATP-competitive pan-PIM inhibitor with anti-cancer and anti-leukemia activity, used in multiple myeloma research.</p>Formule :C18H23N3O3SDegré de pureté :99.49%Couleur et forme :SolidMasse moléculaire :361.46M-110
CAS :<p>M-110 selectively targets PIM kinases, best at PIM-3 (IC50=47nM), and inhibits prostate cancer cell growth (IC50=0.6-0.9μM).</p>Formule :C22H28ClN5O3Degré de pureté :99.55%Couleur et forme :SolidMasse moléculaire :445.94JAK1-IN-4
CAS :<p>JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).</p>Formule :C26H32FN9O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :521.59JAK3/BTK-IN-2
CAS :<p>JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.</p>Formule :C25H32N8O2Degré de pureté :99.64% - 99.87%Couleur et forme :SolidMasse moléculaire :476.57Lorpucitinib
CAS :<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Formule :C22H28N6O2Degré de pureté :99.72%Couleur et forme :SolidMasse moléculaire :408.5JAK3i
CAS :<p>JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.</p>Formule :C18H15FN4O3Degré de pureté :98.61% - 99.81%Couleur et forme :SolidMasse moléculaire :354.34Jaspamycin
CAS :<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>Formule :C12H12N4O5Couleur et forme :SolidMasse moléculaire :292.25PIM-1 Inhibitor 2
CAS :<p>PIM-1 Inhibitor 2 (PIM1-IN-2) is a potent Pim-1 inhibitor with potential anti-cancer activity, used in cancer research.</p>Formule :C17H11ClN4ODegré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :322.75JAK1-IN-8
CAS :<p>JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).</p>Formule :C22H23FN4O3SDegré de pureté :98.4%Couleur et forme :SolidMasse moléculaire :442.51STS-E412
CAS :<p>STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.</p>Formule :C15H15ClN4O2Degré de pureté :99.01%Couleur et forme :SolidMasse moléculaire :318.76Izencitinib
CAS :<p>Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.</p>Formule :C22H26N8Degré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :402.50JAK-STAT-IN-1
CAS :<p>JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.</p>Formule :C21H21N5O2Degré de pureté :99.59%Couleur et forme :SolidMasse moléculaire :375.42Butyzamide
CAS :<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Formule :C29H32Cl2N2O5SDegré de pureté :99.51% - 99.83%Couleur et forme :SoildMasse moléculaire :591.55NT219
CAS :<p>NT219 is a dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3 that enhances the aggregation of misfolded prion proteins NT219 Effects.</p>Formule :C16H14BrNO5SDegré de pureté :98.06% - 99.72%Couleur et forme :SolidMasse moléculaire :412.26Brepocitinib
CAS :<p>Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).</p>Formule :C18H21F2N7ODegré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :389.4Lepzacitinib
CAS :<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Formule :C18H21N5O3Degré de pureté :99.85%Couleur et forme :SolidMasse moléculaire :355.39PM-43I
CAS :<p>PM-43I is a potent inhibitor of both STAT5- and STAT6-dependent allergic airway disease in mice.</p>Formule :C38H50F2N3O10PCouleur et forme :SolidMasse moléculaire :777.79JAK-IN-26
CAS :<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Formule :C22H24N6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :420.46TCS 21311
CAS :<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Formule :C27H25F3N4O4Degré de pureté :99.39% - ≥98%Couleur et forme :SolidMasse moléculaire :526.51STAT3-IN-14
CAS :<p>STAT3-IN-14 is a STAT3 inhibitor and has STAT3 phosphorylation inhibitory activity. STAT3-IN-14 can directly bind to the hinge region of STAT3 .</p>Formule :C14H10O5Couleur et forme :SolidMasse moléculaire :258.23Pim-1 kinase inhibitor 5
CAS :<p>Pim-1 kinase inhibitor 5 (Compound 4c), with an IC50 of 0.61 μM, exhibits cytotoxicity against various cancer cell lines, including HepG2, MCF-7, PC3, and HCT-</p>Formule :C22H13Cl2N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :406.26JAK-IN-24
CAS :<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Formule :C20H25N5O2Couleur et forme :SolidMasse moléculaire :367.44JAK kinase-IN-1
CAS :<p>JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32</p>Formule :C17H19F2N7OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :407.44PIM1-IN-4
CAS :<p>PIM1-IN-4: strong PIM1 inhibitor, also blocks SGK-1, PKA, CaMK-1, GSK3β, MSK1; promising for cancer studies.</p>Formule :C27H25BrCl2CuN6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :663.88JAK-IN-1
CAS :<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Formule :C20H24N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :380.44GNE-955
CAS :<p>GNE-955 is a potent and orally active inhibitor of pan Pim kinase (Kis: 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively).</p>Formule :C22H24N8ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :416.48PIM1-IN-1
CAS :<p>PIM1-IN-1 inhibits PIM1/3 with IC50s: PIM1 (7 nM), PIM2 (5530 nM), PIM3 (70 nM); it has anti-cancer properties.</p>Formule :C25H30N8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :474.56Tubulin/JAK2-IN-1
CAS :<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Formule :C22H20N6O3Couleur et forme :SolidMasse moléculaire :416.43Ginsenoside Rk1
CAS :<p>Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures.</p>Formule :C42H70O12Degré de pureté :98.46% - 99.13%Couleur et forme :SolidMasse moléculaire :767Upadacitinib tartrate
CAS :<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Formule :C21H33F3N6O11Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :602.521JAK-IN-25
CAS :<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Formule :C19H17N5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :379.37Tyk2-IN-9
CAS :<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Formule :C20H17N9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :383.41JAK-IN-4
CAS :<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Formule :C18H21N4Na2O6PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :466.341Nezulcitinib
CAS :<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Formule :C30H37N7O2Couleur et forme :SolidMasse moléculaire :527.66JAK2-IN-4
CAS :<p>JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.</p>Formule :C23H27N5O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :469.56JAK-IN-5
CAS :<p>JAK-IN-5 is a JAK inhibitor.</p>Formule :C27H31FN6ODegré de pureté :98.1% - 99.37%Couleur et forme :SolidMasse moléculaire :474.57STAT3 degrader-2
CAS :<p>STAT3 Degrader-2 is a PROTAC-based compound that effectively reduces the total STAT3 protein levels, and is utilized in the research of cancer and various</p>Formule :C59H62N9O13PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1136.15TCJL37
CAS :<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Formule :C17H11ClF2N4O2Couleur et forme :SolidMasse moléculaire :376.74JAK-IN-31
CAS :<p>JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,</p>Formule :C21H19N7O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :465.55QL-1200186
CAS :<p>QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production following</p>Formule :C26H27N7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :485.54Itacnosertib (hydrocholide)
CAS :<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Formule :C26H29ClN8OCouleur et forme :SolidMasse moléculaire :505.01FM-479
CAS :<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Formule :C25H26N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :442.523JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Formule :C33H38F2N6O8Couleur et forme :SolidMasse moléculaire :684.69ABBV-712
CAS :<p>ABBV-712 is a selective Tyrosine Kinase 2 (TYK2) inhibitor, demonstrating an IC50 value of 0.195 μM, and is implicated in the regulation of autoimmune diseases</p>Formule :C24H28N4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :452.5PIM-IN-2
CAS :<p>PIM-IN-2 (Pim-2) is a potent inhibitor of Pim kinases, demonstrating an inhibition concentration half-maximal (IC50) value of 25 nM .</p>Formule :C19H22N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :338.4STAT6-IN-1
CAS :<p>STAT6-IN-1: STAT6 inhibitor, IC50=0.028 µM, targets SH2 domain, for allergy and cancer research.</p>Formule :C33H37IN3O7PCouleur et forme :SolidMasse moléculaire :745.54FD1024
CAS :<p>FD1024 is a potent PIM inhibitor, displaying inhibitory concentrations (IC50s) of 1.96 nM, 38.9 nM, and 4.17 nM for PIM1, PIM2, and PIM3, respectively.</p>Formule :C21H20F2N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :430.47HS94
CAS :<p>HS94 (DAPK3 inhibitor HS94) is a selective and potent DAPK3 inhibitor with a Ki value of 126 nM for Pim kinase inhibition and can be used to study hypertension.</p>Formule :C15H15N5O2SDegré de pureté :95.04%Couleur et forme :SolidMasse moléculaire :329.38JAK-IN-3
CAS :<p>JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.</p>Formule :C18H20N4O3Degré de pureté :98.04% - 98.19%Couleur et forme :SolidMasse moléculaire :340.38JAK1-IN-9
CAS :<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Formule :C16H13IN6Couleur et forme :SolidMasse moléculaire :416.22GDC-9918
CAS :<p>GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.</p>Formule :C20H18F2N6O5SCouleur et forme :SolidMasse moléculaire :492.46Cenacitinib
CAS :<p>Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.</p>Formule :C19H19F2N7O3Couleur et forme :SolidMasse moléculaire :431.40YLIU-4-105-1
CAS :<p>YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.</p>Formule :C32H34F3N7O2Couleur et forme :SolidMasse moléculaire :605.65JAK2 JH2 binder-1
CAS :<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Formule :C29H25N7O6SCouleur et forme :SolidMasse moléculaire :599.62Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Formule :C18H20F6N4OCouleur et forme :SolidMasse moléculaire :422.37STAT3-IN-7
CAS :<p>STAT3-IN-7, an orally active aryl sulfonamido azetidine compound, serves as a STAT3 inhibitor with anticancer activities.</p>Formule :C30H26F5N5O4SCouleur et forme :SolidMasse moléculaire :647.62JAK1/TYK2-IN-3
<p>JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.</p>Couleur et forme :SolidJAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Formule :C23H22Cl2N4OCouleur et forme :SolidMasse moléculaire :441.35TYK2 ligand 2
CAS :<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Formule :C24H20FN7O4Couleur et forme :SolidMasse moléculaire :489.458iBFAR2
CAS :<p>iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.</p>Formule :C19H15F3N2O2Couleur et forme :SolidMasse moléculaire :360.33JAK3 covalent inhibitor-1
CAS :<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Formule :C22H17FN6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.47AJI-100
CAS :<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Formule :C17H14FN5OCouleur et forme :SolidMasse moléculaire :323.32AJI-214
CAS :<p>AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).</p>Formule :C17H13ClFN5OCouleur et forme :SolidMasse moléculaire :357.77Tyk2-IN-3
CAS :<p>Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).</p>Formule :C25H24N6O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :520.63(3S,4R)-Tofacitinib
CAS :<p>(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).</p>Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37SI-109
CAS :<p>SI-109 is a potent inhibitor of STAT3 SH2 domain (Ki=9 nM),and with antitumor activity.</p>Formule :C40H44F2N7O9PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :835.79(R)-9b
CAS :<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Formule :C20H27ClN6OCouleur et forme :SolidMasse moléculaire :402.92JAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Formule :C20H15ClF3N3OSCouleur et forme :SolidMasse moléculaire :437.87JAK2-IN-11
CAS :<p>JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.</p>Formule :C31H31F3N8O4Couleur et forme :SolidMasse moléculaire :639.64PF-06263276
CAS :<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Formule :C31H31FN8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :566.63lirucitinib
CAS :<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Formule :C16H25N5OSCouleur et forme :SolidMasse moléculaire :335.468JAK3-IN-7
CAS :<p>JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after</p>Formule :C17H20N6ODegré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :324.38LNK01004
CAS :<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Formule :C26H31N7O2Couleur et forme :SolidMasse moléculaire :473.57AZ-3
CAS :<p>AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).</p>Formule :C20H28FN7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :385.48Milpecitinib
CAS :<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Formule :C20H20N4O2SCouleur et forme :SolidMasse moléculaire :380.463Prohibitin ligand 1
<p>Compound 22i, a prohibitin ligand, protects the heart at nanomolar levels by inducing STAT3 phosphorylation.</p>Formule :C20H22N2OCouleur et forme :SolidMasse moléculaire :306.4GDC-0339
CAS :<p>GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.</p>Formule :C20H22F3N7OSCouleur et forme :SolidMasse moléculaire :465.5CEE321
CAS :<p>CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.</p>Formule :C18H16ClN5OCouleur et forme :SolidMasse moléculaire :353.806JAK-IN-19
<p>JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).</p>Formule :C26H36FN5O2Couleur et forme :SolidMasse moléculaire :469.59CP-352664
CAS :<p>CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.</p>Formule :C18H18N4Couleur et forme :SolidMasse moléculaire :290.36Londamocitinib
CAS :<p>Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.</p>Formule :C28H31F2N7O4SDegré de pureté :98.64% - 99.56%Couleur et forme :SolidMasse moléculaire :599.65Tyk2-IN-14
CAS :<p>Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].</p>Formule :C22H21N9O2Couleur et forme :SolidMasse moléculaire :443.46Tyk2-IN-15
CAS :<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Formule :C21H25F2N7OCouleur et forme :SolidMasse moléculaire :429.47Pim-1 kinase inhibitor 6
CAS :<p>Pim-1 kinase inhibitor 6 (Compound 4d) is a robust inhibitor of Pim-1 kinase, demonstrating an IC 50 of 0.46 μM. It significantly exhibits cytotoxic effects on cancer cells [1].</p>Formule :C21H10BrCl2N3Couleur et forme :SolidMasse moléculaire :455.13Tyk2-IN-17
CAS :<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Formule :C20H20F2N8OCouleur et forme :SolidMasse moléculaire :426.42JAK1/TYK2-IN-4
CAS :<p>JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].</p>Formule :C17H23N7OCouleur et forme :SolidMasse moléculaire :341.41JAK3-IN-11
CAS :<p>JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.</p>Formule :C23H23N5O2Couleur et forme :SolidMasse moléculaire :401.46Tyk2-IN-20
CAS :<p>Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.</p>Formule :C24H25N7O2Couleur et forme :SolidMasse moléculaire :443.50JDTic
CAS :<p>JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.</p>Formule :C28H39N3O3Couleur et forme :SolidMasse moléculaire :465.63(3R,4S)-Tofacitinib
CAS :<p>(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.</p>Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37JAK2-IN-9
CAS :<p>Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.</p>Formule :C20H24N6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :412.51JAK-IN-27
CAS :<p>JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM</p>Formule :C20H21F2N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :413.42JAK1-IN-10
CAS :<p>JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].</p>Formule :C15H17N7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :295.34JAK-IN-34
CAS :<p>JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,</p>Formule :C27H26N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :450.53STAT3-IN-18
CAS :<p>STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and</p>Formule :C18H24Cl2N2O6PtDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :630.38JAK1-IN-11
CAS :<p>JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.</p>Formule :C26H36N6O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :528.67DPP
CAS :<p>DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating</p>Formule :C36H40Cl2N2O10PtDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :926.7
